A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Central Nervous System Metastases|Male Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: irinotecan hydrochloride|OTHER: laboratory biomarker analysis
Sponsor: University of California, Irvine